期刊文献+

人凝血因子Ⅷ cDNA在鼠体内的转染与表达

The transfection and expression of human coagulation factor Ⅷ in rats
下载PDF
导出
摘要 目的逆转录病毒载体介导的人凝血因子Ⅷ(FⅧ)鼠肝细胞BRL-3A,通过门静脉途径输入后,观察其在鼠体内的表达。方法将一B区缺失(760~1639aa)的人FⅧcDNA(FⅧBDcDNA)克隆至逆转录病毒载体pLNCX2,构建重组表达载体pLNCX2-FⅧBD,感染BRL-3A细胞。将转染后的靶细胞经门静脉输注到大鼠体内,通过免疫组化法和ELISA法检测人FⅧ在大鼠体内的表达。结果在输注后第1天可检测到人FⅧ抗原,平均为7.2ng/mL大鼠血浆,可持续表达20天;输注的细胞主要分布在肝、脾,在第30天细胞的数目没有明显减少。结论 pLNCX2-FⅧBD转染BRL-3A细胞输注Buffalo大鼠体内后,获得短暂的人FⅧ的生理水平表达,可持续20天左右,为基因治疗血友病A奠定了基础。 Objective To observe the expression of retroviral-mediated high efficient expression system of human coagulation factor Ⅷ in rat,which was inputted through portal vein.Methods The retroviral vector pLNC-FⅧBD was generated by cloning a B-domain-deleted FⅧ cDNA(760~1 639 aa)into retroviral vector pLNCX2,then the BRL-3A cells were transfected.The transfected cell was inputted through portal vein in rat,then the expression of human coagulation factor Ⅷ was measured by ELISA assay and immunohistochemistry method,respectively.Results The FⅧ:Ag was 7.2 ng/mL in rat plasma at 1 day after infusion,which lasted to 20 days and there was no reduction in quantity obviously at 30 days.The target cells mainly distributed in liver and spleen.Conclusion The transfected BRL-3A cells by pLNCX2-FⅧBD are able to generate physiology level expression of human FⅧ after infusion in Buffalo rats and last about 20 days.It may have potential utility in the gene therapy for Hemophilia A.
出处 《胃肠病学和肝病学杂志》 CAS 2010年第6期530-532,共3页 Chinese Journal of Gastroenterology and Hepatology
基金 黑龙江省青年基金资助项目(QC04C17)
关键词 载体 病毒 凝血因子Ⅷ 基因表达 Vector Retroviral Blood coagulation factor Ⅷ Gene expression
  • 相关文献

参考文献7

  • 1Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor[J]. Nature, 1984, 312 ( 5992 ) : 342-347.
  • 2Gitschier J, Wood WI, Goralka TM, et al. Characterization of human factor Ⅷgene [J]. Nature, 1984, 312(5992): 326-330.
  • 3Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A [ J]. Proc Natl Acad Sci U S A, 1998, 95(10) : 5734-5739.
  • 4Hoeben RC, Fallaux FJ, Van Tilburg NH, et al. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice [ J]. Hum Gene Ther, 1993, 4(2) : 179-186.
  • 5Dwarki V J, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A : production of therapeutic levels of human factor VIII in vivo in mice [J]. Proc Natl Acad Sci U S A, 1995, 92 (4) : 1023-1027.
  • 6Sandberg H, Ahnstedt A, Brandt J, et al. Structural and functional characterization of B-domain deleted recombinant factor VIII [ J]. Semin Hematol, 2001, 38(2) : 4-12.
  • 7Saenko EL, Ananyeva NM, Moayeri M, et al. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A [J]. Curr Gene Ther, 2003, 3(1) : 27-41.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部